Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company’s subsidiary Algernon Neuroscience has announced it has completed dosing of the second cohort in the Phase 1 clinical study of DMT. Moreau telling Proactive this study is to identify the safety and tolerability of DMT when administered as an intravenous bolus followed by a prolonged infusion of 6 hours which has never been studied clinically.
Algernon NeuroScience reports successful 2nd Cohort dosing in DMT clinical study
